TX-FLUENCE
23.9.2021 17:56:11 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its upcoming schedule of speakers who will present at virtual and in-person horticulture and cannabis industry conferences this fall.
“We’re thrilled our speakers are joining industry thought leaders from across the world to share their deep knowledge with cultivators, researchers, partners and others,” said David Cohen, CEO of Fluence. “At Fluence, our experts lead with science and are dedicated to advancing the industry’s awareness and application of LED lighting technologies to better understand the interaction between light and life. We look forward to connecting with conference participants, engaging in valuable conversations and discussing insights and learnings about what’s possible for LED lighting technology.”
Fluence’s roster of speakers includes:
- NCIA’s Midwest Cannabis Business Conference : Corinne Wilder, vice president of global operations, will speak with Dario Boyce from Anderson Porter Design and Jesse Porter from Inspire Transpiration Solutions on Sept. 23 at 12:00 p.m. CST about guidelines and policy for resource efficiency, including HVAC, lighting and control systems.
- NYC AgTech Week : Steve Graves, vice president of business development, will speak with Alina Zolotareva from AeroFarms, Tisha Livingston from Infinite Acres, Dr. Mary Ellis from Earle & Associates Ltd. and Penny McBride from FarmTech Society on Sept. 24 at 1:45 p.m. CST about trends in global controlled environment agriculture.
-
GreenTech Amsterdam
:
- Timo Bongartz, general manager of EMEA, will speak with Brad Nattrass from urban-gro and Nic Easley from 3C Consulting, LLC on Sept. 29 at 8:00 a.m. CST about market insights, challenges and opportunities for medical cannabis.
- Leo Lansbergen, horticulture service specialist, will speak with Max van den Hemel from Delphy Improvement Centre, Marc van Oers from Van Iperen International and Eri Hayashi from the Japan Plant Factory Association on Sept. 28 at 5:15 a.m. CST about crop management and optimization.
- Theo Tekstra, technical director, will speak with Lisanne Meulendijks from Delphy Improvement Centre, Andrew Jenkins from TU Delft and Aleksander Nastov from Samsung on Sept. 29 at 7:00 a.m. CST about vertical farming.
- HortiCann Light + Tech : Dr. Abhay Thosar, director of horticulture services, will speak with Adam Shinners from Superior Fresh on Sept. 29 at 3:00 p.m. CST about sustainability and best cultivation practices, efficiencies and optimized lighting strategies in commercial food production.
- Indoor Ag-Con : Steve Graves, vice president of business development, will participate in a panel on Oct. 4 at 9:30 a.m. CST about the next technical frontier for lighting.
- Benzinga Cannabis Capital Conference : David Cohen, CEO of Fluence, will give an exclusive on-stage interview during Benzinga’s hybrid event on Oct. 15 at 12:10 p.m. CST.
- MJBizCon : Corinne Wilder, vice president of global operations, will speak with David Hess from Tress Capital and Derek Smith from the Resource Innovation Institute on Oct. 22 at 12:30 p.m. CST about environmental and sustainability practices.
- 2021 Plant Lighting Short Course : Dr. David Hawley, principal scientist, will speak on Oct. 28 at 1:00 p.m. CST about lighting for indoor agriculture.
- Grow Up Conference & Expo : Taylor Kirk, horticulture service specialist, will join cannabis experts on Dec. 1 at 9:15 a.m. CST to discuss growers’ experiences and expectations with LED lighting in cannabis cultivation.
For information about Fluence’s upcoming speaking engagements, including more presentation details, how to register and how to contact the Fluence team at their upcoming conferences, visit www.fluence.science/events-main .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005773/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom